The temporal effects of IL-33 in these models may also be, to some extent, dose-dependent, as mice which received IL-33 peritransplant and were protected from GVHD received more than twice the dose over a much longer treatment window (81) than those that received posttransplant IL-33 (79). The gene discussed is IL33; the disease is graft versus host disease.